



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

23 September 2011
EMA/770530/2011
Press Office

Overview of designated orphan medicines that have been the subject of a centralised application for marketing authorisation

CHMP meeting 18-22 September 2011

Update since the July 2011 CHMP meeting

Active substance	Invented name	Sponsor/Applicant	EU designation number	Designated orphan indication
Bosutinib	Bosulif	Pfizer Limited	EU/3/10/762	Treatment of chronic myeloid leukaemia

